Entero Therapeutics (NASDAQ:GRDX) Releases Quarterly Earnings Results

Entero Therapeutics (NASDAQ:GRDX) posted its earnings results on Friday. The company reported ($2.01) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.09 million for the quarter.

Entero Therapeutics Trading Down 4.8%

Shares of NASDAQ GRDX traded down $0.18 during midday trading on Friday, hitting $3.57. 158,477 shares of the company traded hands, compared to its average volume of 118,222. Entero Therapeutics has a 12-month low of $1.73 and a 12-month high of $6.93. The company has a market capitalization of $24.68 million, a price-to-earnings ratio of -1.90 and a beta of 1.86. The firm has a 50-day moving average of $3.91.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC bought a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.